drugset
drugset / Trial / NCT05791201

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

NCT05791201 ↗

Phase 1/2 Active not recruiting 7 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Timeline

Start
2023-05-16
Primary completion
2027-03-12
Completion
2027-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-264 Cell therapy — —

Indications

type 1 diabetes mellitus